Sermorelin vs. Ipamorelin vs. CJC-1295: What the Evidence on Growth-Hormone Secretagogues Actually Shows

Telehealth clinics sell sermorelin, ipamorelin, and CJC-1295 as interchangeable members of a category — "GH peptides," "growth hormone secretagogues," sometimes just "GH boosters" — and the pitch is usually the same regardless of which one lands in the vial: more lean mass, better sleep, slower aging, a gentler alternative to injecting growth hormone itself. What the marketing rarely explains is that these three compounds don't share a mechanism, don't share a regulatory history, and don't share an evidence base. Two of them work through one receptor; the third works through a completely different one. This is a companion to our sermorelin provider rankings, which grade who sells this class of compound and how honestly — this article is about what the compounds themselves are actually shown to do.

Two receptors, not one

Sermorelin and CJC-1295 are both GHRH analogs — truncated or re-engineered versions of growth-hormone-releasing hormone, the signal the hypothalamus itself uses to tell the pituitary to release GH. CJC-1295 was built specifically to fix GHRH's biggest practical problem: natural GHRH and sermorelin (a 29-amino-acid fragment of it) are cleared from the body within minutes, so the lab that developed CJC-1295 modified the molecule to resist that breakdown and bind serum albumin, extending its action from minutes to days¹.

Ipamorelin is not a GHRH analog at all. It's a ghrelin-receptor agonist — a small pentapeptide that activates the same "GHRP-like receptor" ghrelin itself binds, a mechanistically distinct pathway from the GHRH receptor. The peptide's own discovery paper describes it as the first such compound shown to be selective: in pigs, doses more than 200-fold above what triggered GH release did not raise cortisol or ACTH the way older ghrelin-receptor compounds (GHRP-6, GHRP-2) did in the same experiments². That selectivity claim is real and well-documented — but it comes from pituitary cells, anesthetized rats, and conscious pigs, not from a controlled human trial measuring anything past a hormone level.

Sermorelin's actual evidence base is a pediatric drug

Sermorelin has the longest track record of the three, and it is almost entirely a pediatric one. The compound's own clinical-review literature is titled, plainly, around "the diagnosis and treatment of children with idiopathic growth hormone deficiency"³ — that was the population sermorelin was developed and evaluated in. The FDA's own drug-approval database confirms this history directly: sermorelin acetate was approved under the brand name Geref in 1990, then granted orphan-drug status in 1997 for a new dosage form — orphan designations exist specifically for rare-disease indications, and pediatric GHD is one. Geref's marketing status today is "Discontinued," with FDA's own database carrying the note that the discontinuation was not for safety or effectiveness reasons — the product was simply pulled from commercial production⁴.

None of that is evidence against sermorelin working as a GHRH agonist; it plainly does. It's evidence about who it was studied in. The population telehealth companies sell it to today — healthy or midlife adults without a diagnosed pituitary condition, chasing body composition or energy — is not the population that generated sermorelin's approval history. The closest thing to real-world data in that adult population is thin: a 2017 retrospective chart review of 105 men already on testosterone therapy, of whom only 14 met strict inclusion criteria, prescribed a combination of sermorelin and two other GH-releasing peptides (GHRP-2, GHRP-6) together — not sermorelin alone. IGF-1 levels rose significantly over a mean 134 days of treatment, but the design was retrospective, uncontrolled, and combined three different secretagogues into one regimen, which means it cannot isolate what sermorelin itself contributed⁵. A 2020 review of GH secretagogues in hypogonadal men reaches a similar note of caution about the broader class: real interest, real biological plausibility, but a published evidence base that is small and mostly short-term⁶.

CJC-1295: real biomarker data in healthy adults, over weeks — not outcome data

CJC-1295 has the best-controlled human data of the three, and it's worth being precise about exactly what that data does and doesn't show. The compound's foundational human trial was two randomized, placebo-controlled, double-blind, ascending-dose studies — 28 and 49 days long — in healthy adults aged 21 to 61. A single injection produced dose-dependent increases in GH (2- to 10-fold) sustained for six or more days, and in IGF-1 (1.5- to 3-fold) for nine to eleven days; the estimated half-life was 5.8 to 8.1 days, and after repeated dosing IGF-1 stayed elevated for up to 28 days. No serious adverse reactions were reported, and effects appeared most favorable at 30 or 60 micrograms/kg⁷.

That is genuinely strong evidence that CJC-1295 does what a long-acting GHRH analog is supposed to do: raise and sustain GH and IGF-1 in people who are not growth-hormone deficient. It is not evidence that raising those biomarkers for a few weeks changes body composition, strength, sleep quality, or aging over months or years — the trial wasn't designed to measure any of that, and the citation above is the trial, not a paraphrase of one. Telehealth copy that cites "clinical studies" for CJC-1295's wellness effects is, at best, extrapolating from a pharmacodynamics trial to outcomes that trial never tested.

Ipamorelin: solid mechanism, thin and mixed human evidence

Ipamorelin does have some human data, and it's worth separating the two studies that exist from the marketing claims layered on top of them. A 1999 dose-escalation pharmacokinetic study in eight healthy male volunteers per dose level confirmed the mechanism translates to people: intravenous ipamorelin triggered a single, time-limited pulse of GH release, peaking around 40 minutes after infusion and clearing with a short (roughly 2-hour) half-life⁸. That establishes ipamorelin raises GH acutely in humans — a real, useful, and narrow finding.

The one randomized, placebo-controlled human trial of ipamorelin that tested an actual clinical outcome is not about muscle, fat, or aging at all. It's a 2014 multicenter phase 2 trial of intravenous ipamorelin for postoperative ileus — sluggish bowel function after abdominal surgery — in 114 hospitalized surgical patients, based on ghrelin receptors' separate role in gut motility. The primary endpoint was time to tolerating a solid meal after surgery: 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p = 0.15)⁹. That is the only ipamorelin trial in the published literature with a real clinical endpoint and a placebo arm, and it missed. FDA's own reviewers reached the same read when they later evaluated ipamorelin for compounding purposes: citing that same 2014 trial, FDA concluded there are "no data to support the effectiveness of ipamorelin ... for the proposed [subcutaneous] route of administration" for either growth-hormone deficiency or postoperative ileus¹⁰. A search of the wider literature for anything resembling a controlled trial of ipamorelin for body composition, fat loss, or anti-aging in adults returns nothing — what exists instead is a body of analytical-chemistry and anti-doping-detection papers that use ipamorelin as a reference compound for screening methods, not clinical trials of the peptide itself.

None of the three are FDA-approved for what telehealth sells

Sermorelin's only FDA-approved product, discussed above, is discontinued and was approved for pediatric GHD — not adult wellness, longevity, or body composition. Ipamorelin and CJC-1295 have no FDA-approved drug product at all. FDA's own compounding reviewers state this outright: their briefing document on ipamorelin notes plainly that med spas and wellness clinics market it "likely" as a compounded product "because there are no FDA-approved drug products containing ipamorelin (free base) or ipamorelin acetate"¹⁰. A direct, independent check against DailyMed — the National Library of Medicine's official archive of FDA-approved drug labeling — confirms the same thing for both compounds: zero results for either "ipamorelin" or "CJC-1295"¹¹¹². That is a meaningfully different regulatory status than tirzepatide's, which is FDA-approved and merely subject to a narrowed compounding exception — see our tirzepatide provider comparison if that's the category you're actually shopping. Consistent with all of this, when FDA's Pharmacy Compounding Advisory Committee formally took up CJC-1295 (in every salt and conjugated form nominated) for possible inclusion on the 503A compounding-bulks list in December 2024, FDA's own staff proposed, item by item, that none of those forms be included¹³.

Not under active FDA compounding review, either

FDA maintains a running, dated list of substances nominated for its 503A compounding-bulks list, sorted into three categories: substances under active evaluation (Category 1), substances that raised significant safety concerns (Category 2), and substances nominated without adequate supporting information (Category 3). Reading FDA's own current version of that list — updated May 14, 2026 — none of sermorelin, ipamorelin, or CJC-1295 appear in any of the three categories¹⁴. A related compound, ibutamoren (a different, orally active ghrelin-receptor agonist sometimes sold alongside these three), does sit in Category 2 over safety concerns, and two older GH-releasing peptides, GHRP-2 and GHRP-6, sit in Category 3. Sermorelin, ipamorelin, and CJC-1295 simply aren't on FDA's active-review radar under this specific process at all — consistent with the committee having already been advised against listing them. A pharmacy compounding them today isn't operating inside an FDA "under evaluation, enforcement discretion pending" category the way some other compounded peptides are; it's operating in the older, more general 503A/503B framework, with none of these three named as bulk substances the agency currently evaluates one way or the other.

Banned in tested sport, all three, by name

If you're weighing any of these for athletic performance rather than general wellness, this part is unambiguous. WADA's 2026 Prohibited List — the actual document, not a summary of it — lists growth hormone-releasing factors under category WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), specifically subsection S2.2.4, "Prohibited at all times," as a non-Specified Substance class. The list names CJC-1295 and sermorelin explicitly under "growth hormone-releasing hormone (GHRH) and its analogues," and names ipamorelin explicitly under "growth hormone secretagogues (GHS) and their mimetics" — a separate line from the GHRH analogs, matching the mechanistic split described above¹⁵. All three are banned in and out of competition, with no dose threshold or therapeutic-use exemption built into the class itself. If you're tested under any WADA-code sport, none of these three peptides is a gray area.

What the evidence actually supports — and what it doesn't

Stripped of marketing language: sermorelin has a real, decades-old evidence base for raising GH via the GHRH receptor — generated almost entirely in children with diagnosed growth-hormone deficiency, with only thin, uncontrolled, combination-therapy data in adults without that diagnosis. CJC-1295 has genuinely strong human biomarker data — a real placebo-controlled trial confirming sustained GH/IGF-1 elevation in healthy adults — but no published trial testing whether that translates into the body-composition or longevity outcomes it's marketed for. Ipamorelin has a confirmed human mechanism and exactly one placebo-controlled outcome trial in the literature, for an unrelated surgical-recovery indication, which missed its primary endpoint. None of the three is FDA-approved for adult wellness use, none currently sits under active FDA compounding evaluation, and all three are prohibited by name in tested competitive sport.

How the providers we've reviewed compare

Of the providers our sermorelin rankings currently cover, three actually sell sermorelin. Precision Telemed is the only one of the three that names its compounding pharmacy and states a federal regulatory category for it in writing, though its advertised sermorelin price steps up after the first month. CoreAge Rx advertises the lowest sermorelin floor of the group but names no pharmacy and publishes no price ceiling above that floor. PlexusDx is the one provider here that states outright, in its own words, that compounded medications aren't FDA-approved — a disclosure the other two leave unstated, even though none of the three would need to make it about sermorelin specifically to be accurate, since none of them do. Three more providers on our tirzepatide board — yourEra, Found, and Henry Meds — don't sell sermorelin at all; their catalogs are tirzepatide only, a different drug class entirely (an FDA-approved GLP-1/GIP receptor agonist, not a GH secretagogue). Their own reviews and our tirzepatide comparison are the more relevant reads if that's the category you're actually in the market for. Once a prescriber has actually given you a sermorelin dose in milligrams, our reconstitution calculator converts that into the exact syringe volume and insulin-syringe units it corresponds to.